علاج سرطان الرئة (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "علاج سرطان الرئة" in Arabic language version.

refsWebsite

Global rank Arabic rank

18web.archive.org

1^st place

18nih.gov

4^th place

6^th place

14doi.org

2^nd place

5^th place

9fda.gov

447^th place

393^rd place

3medscape.com

719^th place

243^rd place

1semanticscholar.org

11^th place

86^th place

1iarc.fr

4,025^th place

5,889^th place

1mylungcancersupport.org

low place

1aacrjournals.org

8,869^th place

4,545^th place

1healio.com

low place

7,846^th place

1jci.org

low place

aacrjournals.org

clincancerres.aacrjournals.org

Johnson JR، Cohen M، Sridhara R، وآخرون (سبتمبر 2005). "Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen". Clin. Cancer Res. ج. 11 ع. 18: 6414–21. DOI:10.1158/1078-0432.CCR-05-0790. PMID:16166415. مؤرشف من الأصل في 2020-04-06.

doi.org

Temel JS، Greer JA، Muzikansky A، وآخرون (أغسطس 2010). "Early palliative care for patients with metastatic non-small-cell lung cancer". N. Engl. J. Med. ج. 363 ع. 8: 733–42. DOI:10.1056/NEJMoa1000678. PMID:20818875. مؤرشف من الأصل في 2020-04-06.
Kelley AS، Meier DE (أغسطس 2010). "Palliative care--a shifting paradigm". N. Engl. J. Med. ج. 363 ع. 8: 781–2. DOI:10.1056/NEJMe1004139. PMID:20818881.
Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology (بالإنجليزية). 18 (12): e731–e741. DOI:10.1016/s1470-2045(17)30607-1. PMID:29208439.
Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor". Curr Resp Med Rev. ج. 3: 69–77. DOI:10.2174/157339807779941820.
Vincent MD (أغسطس 2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. ج. 16 ع. 4: 9–21. DOI:10.3747/co.v16i4.465. PMC:2722061. PMID:19672420.
Travis WD، Travis LB، Devesa SS (يناير 1995). "Lung cancer". Cancer. ج. 75 ع. 1 Suppl: 191–202. DOI:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y. PMID:8000996.
Raz، DJ؛ He B؛ Rosell R؛ Jablons DM (مارس 2006). "Bronchioloalveolar carcinoma: a review". Clinical Lung Cancer. ج. 7 ع. 5: 313–322. DOI:10.3816/CLC.2006.n.012. PMID:16640802.
Bencardino، K؛ Manzoni M؛ Delfanti S؛ وآخرون (مارس 2007). "Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues". Internal and Emergency Medicine. ج. 2 ع. 1: 3–12. DOI:10.1007/s11739-007-0002-5. PMC:2780603. PMID:17551677.
Johnson JR، Cohen M، Sridhara R، وآخرون (سبتمبر 2005). "Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen". Clin. Cancer Res. ج. 11 ع. 18: 6414–21. DOI:10.1158/1078-0432.CCR-05-0790. PMID:16166415. مؤرشف من الأصل في 2020-04-06.
Sasaki T، Rodig SJ، Chirieac LR، Jänne PA (يوليو 2010). "The biology and treatment of EML4-ALK non-small cell lung cancer". Eur. J. Cancer. ج. 46 ع. 10: 1773–80. DOI:10.1016/j.ejca.2010.04.002. PMC:2888755. PMID:20418096.
Edelman، MJ (سبتمبر 2006). "Novel cytotoxic agents for non-small cell lung cancer". Journal of Thoracic Oncology. ج. 1 ع. 7: 752–5. DOI:10.1097/01243894-200609000-00032. PMID:17409954.
Lee، JM؛ Mao JT؛ Krysan K؛ Dubinett SM (أبريل 2007). "Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC". Future Oncology. ج. 3 ع. 2: 149–153. DOI:10.2217/14796694.3.2.149. PMID:17381414.
Dragnev، KH؛ Petty WJ؛ Shah SJ؛ وآخرون (مارس 2007). "A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer". Clinical Cancer Research. ج. 13 ع. 6: 1794–1800. DOI:10.1158/1078-0432.CCR-06-1836. PMID:17363535.
Sun، S؛ Schiller JH؛ Spinola M؛ Minna JD (أكتوبر 2007). "New molecularly targeted therapies for lung cancer". Journal of Clinical Investigation. ج. 117 ع. 10: 2740–2750. DOI:10.1172/JCI31809. PMC:1994616. PMID:17909619. مؤرشف من الأصل في 2020-04-06.

fda.gov

Research, Center for Drug Evaluation and (3 Nov 2018). "Atezolizumab (TECENTRIQ)". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (9 Feb 2019). "Pembrolizumab (Keytruda) 5-10-2017". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (9 Feb 2019). "FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (3 Nov 2018). "FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (9 Feb 2019). "FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (14 Dec 2018). "FDA approves atezolizumab with chemotherapy and bevacizumab for first-line treatment of metastatic non-squamous NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (19 Mar 2019). "FDA approves atezolizumab for extensive-stage small cell lung cancer". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (11 Apr 2019). "FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (18 Jun 2019). "FDA approves pembrolizumab for metastatic small cell lung cancer". FDA (بالإنجليزية). Archived from the original on 2020-04-06.

healio.com

"ALK inhibitor crizotinib has high response rate in patients with ALK-positive NSCLC". HemOncToday. 5 يونيو 2010. مؤرشف من الأصل في 2020-04-06. اطلع عليه بتاريخ 2010-06-07.

iarc.fr

Travis، William D؛ Brambilla، Elizabeth؛ Muller-Hermelink، H Konrad؛ وآخرون، المحررون (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN:92-832-2418-3. مؤرشف من الأصل (PDF) في 2020-04-06.

jci.org

Sun، S؛ Schiller JH؛ Spinola M؛ Minna JD (أكتوبر 2007). "New molecularly targeted therapies for lung cancer". Journal of Clinical Investigation. ج. 117 ع. 10: 2740–2750. DOI:10.1172/JCI31809. PMC:1994616. PMID:17909619. مؤرشف من الأصل في 2020-04-06.

medscape.com

Kling, Jim (5 نوفمبر 2010). "Lung-Sparing Surgery Effective for Early-Stage Lung Cancer". Medscape Medical News. مؤرشف من الأصل في 2020-04-06.
Gale, Karla (2 نوفمبر 2010). "Lung Cancer Outcomes Similar With Anatomic Segmentectomy and Lobectomy". Reuters Health Information. مؤرشف من الأصل في 2020-04-06.

emedicine.medscape.com

Non-Small Cell Lung Cancer Treatment & Management~treatment في موقع إي ميديسين

mylungcancersupport.org

"What You Need to Know About Lung Cancer" (بالإنجليزية). Archived from the original on 2020-04-06. Retrieved 2022-05-04.

nih.gov

pubmed.ncbi.nlm.nih.gov

Temel JS، Greer JA، Muzikansky A، وآخرون (أغسطس 2010). "Early palliative care for patients with metastatic non-small-cell lung cancer". N. Engl. J. Med. ج. 363 ع. 8: 733–42. DOI:10.1056/NEJMoa1000678. PMID:20818875. مؤرشف من الأصل في 2020-04-06.
Kelley AS، Meier DE (أغسطس 2010). "Palliative care--a shifting paradigm". N. Engl. J. Med. ج. 363 ع. 8: 781–2. DOI:10.1056/NEJMe1004139. PMID:20818881.
Prince-Paul M (أبريل 2009). "When hospice is the best option: an opportunity to redefine goals". Oncology (Williston Park, N.Y.). ج. 23 ع. 4 Suppl Nurse Ed: 13–7. PMID:19856592.
Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology (بالإنجليزية). 18 (12): e731–e741. DOI:10.1016/s1470-2045(17)30607-1. PMID:29208439.
Vincent MD (أغسطس 2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. ج. 16 ع. 4: 9–21. DOI:10.3747/co.v16i4.465. PMC:2722061. PMID:19672420.
Travis WD، Travis LB، Devesa SS (يناير 1995). "Lung cancer". Cancer. ج. 75 ع. 1 Suppl: 191–202. DOI:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y. PMID:8000996.
Raz، DJ؛ He B؛ Rosell R؛ Jablons DM (مارس 2006). "Bronchioloalveolar carcinoma: a review". Clinical Lung Cancer. ج. 7 ع. 5: 313–322. DOI:10.3816/CLC.2006.n.012. PMID:16640802.
Bencardino، K؛ Manzoni M؛ Delfanti S؛ وآخرون (مارس 2007). "Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues". Internal and Emergency Medicine. ج. 2 ع. 1: 3–12. DOI:10.1007/s11739-007-0002-5. PMC:2780603. PMID:17551677.
Johnson JR، Cohen M، Sridhara R، وآخرون (سبتمبر 2005). "Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen". Clin. Cancer Res. ج. 11 ع. 18: 6414–21. DOI:10.1158/1078-0432.CCR-05-0790. PMID:16166415. مؤرشف من الأصل في 2020-04-06.
Sasaki T، Rodig SJ، Chirieac LR، Jänne PA (يوليو 2010). "The biology and treatment of EML4-ALK non-small cell lung cancer". Eur. J. Cancer. ج. 46 ع. 10: 1773–80. DOI:10.1016/j.ejca.2010.04.002. PMC:2888755. PMID:20418096.
Edelman، MJ (سبتمبر 2006). "Novel cytotoxic agents for non-small cell lung cancer". Journal of Thoracic Oncology. ج. 1 ع. 7: 752–5. DOI:10.1097/01243894-200609000-00032. PMID:17409954.
Lee، JM؛ Mao JT؛ Krysan K؛ Dubinett SM (أبريل 2007). "Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC". Future Oncology. ج. 3 ع. 2: 149–153. DOI:10.2217/14796694.3.2.149. PMID:17381414.
Dragnev، KH؛ Petty WJ؛ Shah SJ؛ وآخرون (مارس 2007). "A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer". Clinical Cancer Research. ج. 13 ع. 6: 1794–1800. DOI:10.1158/1078-0432.CCR-06-1836. PMID:17363535.
Sun، S؛ Schiller JH؛ Spinola M؛ Minna JD (أكتوبر 2007). "New molecularly targeted therapies for lung cancer". Journal of Clinical Investigation. ج. 117 ع. 10: 2740–2750. DOI:10.1172/JCI31809. PMC:1994616. PMID:17909619. مؤرشف من الأصل في 2020-04-06.

ncbi.nlm.nih.gov

Vincent MD (أغسطس 2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. ج. 16 ع. 4: 9–21. DOI:10.3747/co.v16i4.465. PMC:2722061. PMID:19672420.
Bencardino، K؛ Manzoni M؛ Delfanti S؛ وآخرون (مارس 2007). "Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues". Internal and Emergency Medicine. ج. 2 ع. 1: 3–12. DOI:10.1007/s11739-007-0002-5. PMC:2780603. PMID:17551677.
Sasaki T، Rodig SJ، Chirieac LR، Jänne PA (يوليو 2010). "The biology and treatment of EML4-ALK non-small cell lung cancer". Eur. J. Cancer. ج. 46 ع. 10: 1773–80. DOI:10.1016/j.ejca.2010.04.002. PMC:2888755. PMID:20418096.
Sun، S؛ Schiller JH؛ Spinola M؛ Minna JD (أكتوبر 2007). "New molecularly targeted therapies for lung cancer". Journal of Clinical Investigation. ج. 117 ع. 10: 2740–2750. DOI:10.1172/JCI31809. PMC:1994616. PMID:17909619. مؤرشف من الأصل في 2020-04-06.

semanticscholar.org

Temel JS، Greer JA، Muzikansky A، وآخرون (أغسطس 2010). "Early palliative care for patients with metastatic non-small-cell lung cancer". N. Engl. J. Med. ج. 363 ع. 8: 733–42. DOI:10.1056/NEJMoa1000678. PMID:20818875. مؤرشف من الأصل في 2020-04-06.

web.archive.org

Temel JS، Greer JA، Muzikansky A، وآخرون (أغسطس 2010). "Early palliative care for patients with metastatic non-small-cell lung cancer". N. Engl. J. Med. ج. 363 ع. 8: 733–42. DOI:10.1056/NEJMoa1000678. PMID:20818875. مؤرشف من الأصل في 2020-04-06.
Travis، William D؛ Brambilla، Elizabeth؛ Muller-Hermelink، H Konrad؛ وآخرون، المحررون (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN:92-832-2418-3. مؤرشف من الأصل (PDF) في 2020-04-06.
"What You Need to Know About Lung Cancer" (بالإنجليزية). Archived from the original on 2020-04-06. Retrieved 2022-05-04.
Kling, Jim (5 نوفمبر 2010). "Lung-Sparing Surgery Effective for Early-Stage Lung Cancer". Medscape Medical News. مؤرشف من الأصل في 2020-04-06.
Gale, Karla (2 نوفمبر 2010). "Lung Cancer Outcomes Similar With Anatomic Segmentectomy and Lobectomy". Reuters Health Information. مؤرشف من الأصل في 2020-04-06.
Johnson JR، Cohen M، Sridhara R، وآخرون (سبتمبر 2005). "Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen". Clin. Cancer Res. ج. 11 ع. 18: 6414–21. DOI:10.1158/1078-0432.CCR-05-0790. PMID:16166415. مؤرشف من الأصل في 2020-04-06.
"ALK inhibitor crizotinib has high response rate in patients with ALK-positive NSCLC". HemOncToday. 5 يونيو 2010. مؤرشف من الأصل في 2020-04-06. اطلع عليه بتاريخ 2010-06-07.
Sun، S؛ Schiller JH؛ Spinola M؛ Minna JD (أكتوبر 2007). "New molecularly targeted therapies for lung cancer". Journal of Clinical Investigation. ج. 117 ع. 10: 2740–2750. DOI:10.1172/JCI31809. PMC:1994616. PMID:17909619. مؤرشف من الأصل في 2020-04-06.
"Press Announcements - FDA expands approved use of Opdivo to treat lung cancer". wayback.archive-it.org (بالإنجليزية). Archived from the original on 2020-04-06. Retrieved 2019-06-18.{{استشهاد ويب}}: صيانة الاستشهاد: BOT: original URL status unknown (link)
Research, Center for Drug Evaluation and (3 Nov 2018). "Atezolizumab (TECENTRIQ)". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (9 Feb 2019). "Pembrolizumab (Keytruda) 5-10-2017". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (9 Feb 2019). "FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (3 Nov 2018). "FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (9 Feb 2019). "FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (14 Dec 2018). "FDA approves atezolizumab with chemotherapy and bevacizumab for first-line treatment of metastatic non-squamous NSCLC". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (19 Mar 2019). "FDA approves atezolizumab for extensive-stage small cell lung cancer". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (11 Apr 2019). "FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)". FDA (بالإنجليزية). Archived from the original on 2020-04-06.
Research, Center for Drug Evaluation and (18 Jun 2019). "FDA approves pembrolizumab for metastatic small cell lung cancer". FDA (بالإنجليزية). Archived from the original on 2020-04-06.